Sanofi-Aventis (SNY) Says Multaq Study Shows 24% Cut in Cardio Hospitalization/Death -Bloomberg
More News related to SNY
- Sanofi-aventis (SNY) Announes FDA Approval of Multaq for Patients with Atrial Fibrillation or Atrial Flutter
- FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
- Notable Analyst Rating Changes 6/29: DFS, LYG, TRW, BCS, JCP Upgraded; AA, SNY, BIIB, WW Downgraded
- J.P. Morgan Downgrades Sanofi-Aventis (SNY) to Neutral
- Sanofi-aventis Stands Behind the Safety of Lantus(R)
Bloomberg is reporting that Sanofi-Aventis (NYSE: SNY) said Multaq results show statistical significance: Multaq reduced cardio hospitalization/death by 24%.
Related Categories
Corporate NewsStocks Mentioned
-2.78Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
